Rosemary A. Crane
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Certara analysts raise price targets, maintain positive outlook. TD Cowen kept its buy rating on Certara and lifted its price target to $11. Barclays also maintained an equal‑weight stance and increased its target to $9. A Yahoo analysis noted the company's fair‑value estimate moving higher as the turnaround gains traction. The upgrades suggest growing confidence among analysts.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Transaction History
| TEVA | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 | View on chart |
| CERT | ▲ Buy | Option Exercise | 15,757 | $0 | 5/14/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 | View on chart |
| CERT | ▲ Buy | Option Exercise | 11,928 | $0 | 5/21/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/24/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 21,108 | — | 6/15/2024 | View on chart |
| CERT | ▲ Buy | Option Exercise | 8,663 | $0 | 5/21/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,810 | — | 8/4/2023 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,000 | — | 6/16/2023 | View on chart |
| CERT | ▲ Buy | Option Exercise | 9,324 | $0 | 5/23/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 14,479 | — | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.